Valbenazine (Ingrezza®) leads to consistently greater improvements in chorea associated with Huntington disease (HD) compared to placebo, according to new data from a phase 3 clinical trial called KINECT®-HD. “The exploratory analysis from our KINECT-HD study further exemplifies the value of INGREZZA as a now approved medication for HD chorea with improvements seen with treatment as…
Brain glycogen could play a role in disease presentation and progression of Huntington’s disease (HD), according to a study recently published in Disease Models & Mechanisms. “Further, the overexpression of glycogen synthase in the brain rescues photoreceptor degeneration, improves locomotor deficits, and increases fitness traits in Huntington’s disease model,” the authors wrote. This experimental study…
Stressful experiences associated with Huntington disease (HD) are an important risk factor for depression, according to a new study published in the Journal of Neurology. “Our findings support the use of more psychologically informed models of depression in HD and necessitate further research on tailored psychosocial interventions for HD patients with depression,” the authors concluded.…
Metabolites involved in the biosynthesis of aminoacyl-tRNA synthesis could play an important role in the pathogenesis of Huntington’s disease (HD), according to a study recently published in Genes. “This study improves our understanding of molecular biomarker connections and, importantly, increases our knowledge of metabolic alterations driving HD progression,” the authors wrote. Read more about HD…
Delayed saccadic initiation, oculomotor apraxia, could be an early presentation of juvenile-onset Huntington disease (juvenile HD), according to a case report published in Movement Disorders Clinical Practice. Oculomotor apraxia has been reported in about 20% of juvenile HD cases, but it usually occurs later in the disease progression. The patient in the case report, a…
Cholesterol delivery using brain-permeable nanoparticles is a therapeutic option to reverse the behavioral decline related to Huntington disease (HD) and the neuropathological signs of the disease in a mouse model, according to a new study published in the journal Pharmacological Research. These findings “highlight the therapeutic potential of cholesterol-based strategies in HD patients,” the authors…
The interaction between soluble forms of mutant huntingtin protein and key cellular organelles drives the initial steps of the progression of Huntington disease (HD), according to a new study published in the journal Cellular and Molecular Life Sciences. Moreover, the transmission of these mutant huntingtin proteins through exosomes contributes to the spread of the disease in…
Black patients with Huntington disease (HD) who were part of a retrospective cohort study tended to have more severe symptoms at baseline than other racial groups studied according to an article published in Movement Disorders. The Black patients tended to have more impairment on the total functional capacity (TFC) scores, lower processing speed and visual…
Neurocrine Biosciences Incorporated has announced the US Food and Drug Administration (FDA) approval for the use of valbenazine (Ingrezza®) capsules, designed to alleviate chorea, a characteristic movement disorder associated with Huntington disease (HD) in adults, according to a recently published press release. Valbenazine is a selective vesicular monoamine transporter 2 inhibitor characterized by its adaptable…
Please login or register first to view this content.
